Home > Cardiology > ACC 2019 > Pulmonary Arterial Hypertension and Venous Thromboembolism > Apixaban is safe and effective in real-world setting for treatment of venous thromboembolism

Apixaban is safe and effective in real-world setting for treatment of venous thromboembolism


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ACC 2019
Many patients suffering from venous thromboembolism may benefit from real-world data on the direct oral anticoagulant (DOAC) apixaban, which shows a significant lower risk of major bleeding as well as recurrent venous thromboembolism (VTE) when compared with warfarin. A retrospective study of VTE patients receiving outpatient pharmacotherapy with apixaban or warfarin in clinical practice showed that the risks of major bleeding and recurrent VTE were significantly lower among patients who received apixaban. These findings offer the first evidence on safety and effetiveness of apixaban in treating and preventing VTE in a real-world setting [1]. Results from the AMPLIFY trial show that the DOAC apixaban was non-inferior to low-molecular-weight heparin followed by warfarin in treatment of acute VTE. There was also significantly less major bleeding with apixaban [2]. According to clinical practice guidelines, DOACs are recommended over vitamin K antagonists (VK...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on